Tumor necrosis factor antagonists for the treatment of...

Details Tumor necrosis factor antagonists for the treatment of... Tumor necrosis factor antagonists for the treatment of...

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61K 31/42 (2006.01) A61K 31/495 (2006.01) A61K 31/50 (2006.01) C07K 16/24 (2006.01)

Patent

CA 2364130

A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing damage to neuronal tissue or for modulating the immune response affecting neuronal tissue of the human. The TNF antagonist administered is selected from the group consisting of etanercept and infliximab. The TNF antagonist is administered subcutaneously, intravenously, intrathecally, or intramuscularly. Methotrexate or Leflunomide may be administered concurrently with the TNF antagonist for demyelinating diseases and certain other neurological disorders.

Méthode d'inhibition de l'action du facteur de nécrose tumorale TNF dans le traitement d'états neurologiques chez un sujet humain, consistant en l'administration d'un agoniste du TNF afin de réduire la détérioration du tissu neuronal ou de moduler la réponse immune affectant le tissu neuronal du sujet humain. L'antagoniste du TNF administré est sélectionné dans le groupe constitué d'étanercept et d'infliximab. L'antagoniste du TNF est administré par voie sous-cutanée, intraveineuse, intrathécale ou intramusculaire. On peut administrer du méthotrexate ou du léflunomide simultanément à l'antagoniste du TNF contre des maladies démyélinisantes et certains autres troubles neurologiques.

Affiliated with

Also associated with

Rating

Tumor necrosis factor antagonists for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor necrosis factor antagonists for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor necrosis factor antagonists for the treatment of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1364877